About Anna Suk-Fong

Dr. Lok graduated from University of Hong Kong Medical School. She completed her medicine training at Queen Mary Hospital and hepatology training in London under Dame Sheila Sherlock.  She was a faculty at the University of Hong Kong until she moved to the United States in 1992. Dr. Lok joined the University of Michigan in 1995 as Director of the Hepatology Program. She became Associate Chair for Clinical Research in the Department of Internal Medicine in 2008 and Assistant Dean for Clinical Research in 2016. 
Dr. Lok’s research focuses on natural history and treatment of hepatitis B and C. She has published more than 450 papers on viral hepatitis and liver diseases including four iterations of the American Association for the Study of Liver Diseases (AASLD) guidelines on “Hepatitis B”. She also participated in the development of the first World Health Organization guidelines on hepatitis B and C. Dr. Lok has made important contributions to the understanding of factors influencing the progression of hepatitis B and C, and the development of new treatments of these diseases. She was one of the top 1% most cited researchers in the world for the period 2002-2012. Dr. Lok has mentored more than 50 fellows and junior faculty worldwide, many are now professors and heads of their departments. 
Dr. Lok received many awards throughout her career including the Distinguished Scientist Award from the Hepatitis B Foundation and the Distinguished Women Scientist Award from the American Gastroenterological Association (AGA) in 2008, the Distinguished Service Award from the AASLD in 2011, the Distinguished Scientific Achievement Award from the American Liver Foundation in 2015, the William Beaumont Prize in Gastroenterology from the AGA in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver and an Hon DSc from the University of Hong Kong in 2017.
Dr. Lok served as Associate Editor of HEPATOLOGY in 2002-6, co-Editor of Journal of Viral Hepatitis in 2007-9 and a Senior Associate Editor of GASTROENTEROLOGY in 2011-2012. 
Dr. Lok is currently President of the AASLD.

This speaker will be presenting at the following session(s)

  • Making elimination a reality

    Plenary

    Day: 1 November

    Time: 11:30

    This opening plenary session looks at the opportunities and challenges that lie ahead in the global implementation of viral hepatitis plans.

    Worldwide, approximately 257 million people have chronic hepatitis B infection and 71 million people have chronic hepatitis C infection - two liver infections that together result in an estimated 1.34 million deaths worldwide. A stepped-up global response can no longer be delayed.

    This session will bring together a group of visionaries from all walks of life who champion the cause of elimination to participate in a dialogue around achieving the common goal of elimination.

  • Liver societies’ role towards global elimination of hepatitis

    Side meeting

    Day: 2 November

    Time: 07:30

    Presented by AASLD, EASL and ALEH, this early morning side meeting will look at the role of the professional medical societies in the viral hepatitis elimination plan.